Emapunil attenuates ulcerative colitis by suppressing Z-DNA binding protein 1 driven pyroptosis and pro-inflammatory polarization in macrophages

Ulcerative colitis (UC) is a chronic inflammatory bowel disease whose exact causes remain poorly understood, making targeted treatment difficult. This study investigated a protein called ZBP1 (Z-DNA binding protein 1), which the researchers found to be abnormally elevated in immune cells called macrophages within the colon lining of UC patients. When ZBP1 is overactive, it triggers a particularly destructive form of cell death called pyroptosis, which releases a flood of inflammatory signals and also skews macrophages toward a damaging pro-inflammatory state — together these events erode the protective gut barrier. The researchers then tested Emapunil, a drug that acts on a mitochondrial membrane protein called TSPO, and found it could dial down ZBP1 expression, reduce macrophage pyroptosis, and restore a more balanced immune response. In mouse models of DSS-induced colitis, Emapunil reduced colon injury and preserved barrier integrity. The study identifies the TSPO–ZBP1 axis as a previously unrecognised control point in UC-associated macrophage dysfunction. While the work is preclinical, it proposes a mechanistically distinct therapeutic strategy that could complement existing UC therapies.

• ZBP1 was significantly upregulated in colorectal macrophages isolated from human UC patients compared with controls, establishing clinical relevance for the pathway before any experimental manipulation.
• Forced overexpression of ZBP1 in macrophages induced pyroptotic cell death, drove M1 (pro-inflammatory) polarisation, activated the NF-κB signalling pathway, and impaired intestinal epithelial barrier integrity in vitro; conversely, ZBP1 knockdown markedly reversed all of these effects, confirming ZBP1 as a causal driver rather than a bystander.
• Emapunil, acting through TSPO, suppressed ZBP1 expression, reduced macrophage pyroptosis and inflammatory polarisation, alleviated DSS-induced colonic histological injury, and preserved intestinal barrier function in mice, demonstrating in vivo therapeutic efficacy.

The study used a multi-model design combining human tissue analysis, in vitro macrophage experiments, and an in vivo mouse model. Immunofluorescence was applied to colorectal biopsies from UC patients and DSS-induced colitis mice to localise and quantify ZBP1 expression. In cultured macrophages, ZBP1 was manipulated via overexpression constructs and knockdown approaches, and Emapunil was applied as a pharmacological intervention; readouts included pyroptosis markers, polarisation phenotype (M1/M2), NF-κB pathway activation, and co-culture-based intestinal barrier integrity assays. Therapeutic effects of Emapunil were validated in the DSS mouse colitis model with assessments of colonic injury and barrier function. Exact sample sizes, DSS concentrations, and Emapunil doses are reported in the primary article but were not specified in the abstract.

As a preclinical study using DSS-induced colitis in mice and immortalised or primary macrophage cultures, the findings cannot be directly extrapolated to human pharmacology, dosing, or safety — DSS colitis recapitulates acute mucosal injury but does not fully model chronic human UC. The study does not address whether ZBP1 upregulation is a cause or consequence of the broader inflammatory milieu, nor does it resolve the upstream trigger that initially elevates ZBP1 in UC macrophages. Emapunil's TSPO-targeting mechanism may have pleiotropic effects beyond ZBP1 suppression that could confound mechanistic attribution. The next critical experiment would be a human macrophage-based validation using primary cells from UC patients alongside TSPO/ZBP1 genetic association analyses, followed by early-phase dose-finding safety studies.

This article extends [§146], which demonstrates that intermittent fasting alleviates UC through lithocholic-acid-mediated macrophage reprogramming, by providing an entirely distinct pharmacological node — the TSPO–ZBP1 axis — through which macrophage pyroptosis and polarisation can be corrected, suggesting that macrophage re-education in UC is amenable to multiple upstream interventions. It parallels [§120], which shows that Eubacterium rectale mitigates IBD via glutamine metabolism and NF-κB modulation, since both studies converge on NF-κB as a critical effector pathway downstream of divergent initiating signals (ZBP1-driven pyroptosis versus bacterial metabolite sensing). The work also contextualises [§118], a polysaccharide-based DSS-colitis intervention study, by highlighting that gut barrier preservation can be achieved through immunological (macrophage pyroptosis suppression) as well as microbiota-modulatory routes, reinforcing the centrality of the mucosal barrier as a therapeutic endpoint across mechanistically distinct approaches. Together, these comparisons situate the TSPO–ZBP1–NF-κB circuit as one of several converging innate immune nodes whose dysregulation drives UC pathology.

• Intermittent fasting alleviates ulcerative colitis via lithocholic acid-mediated macrophage reprogramming
  Both target macrophage dysfunction in UC but through entirely different upstream mechanisms — TSPO/ZBP1 pharmacological suppression versus lithocholic-acid metabolic reprogramming — making direct mechanistic comparison valuable for understanding which macrophage activation nodes are most therapeutically tractable.
• Eubacterium rectale Mitigates Inflammatory Bowel Disease via Modulation of Glutamine Metabolism Through the GLS2 and NF-κB Pathway
  Both studies implicate NF-κB as a key effector in colitis macrophage pathology but via distinct triggers (ZBP1-driven pyroptosis versus bacterial glutamine metabolism), offering a useful side-by-side view of how diverse upstream signals funnel into the same inflammatory pathway.
• Anti-inflammatory and gut microbiota-modulating effects of a novel mannan from Scilla scilloides on DSS-induced colitis in mice
  Both use the DSS mouse colitis model and assess intestinal barrier integrity as a primary endpoint, allowing methodological comparison of a pharmacological macrophage-targeted approach (Emapunil) versus a prebiotic polysaccharide intervention on overlapping outcome measures.
• Ulcerative colitis-driven gut dysbiosis exacerbates periodontal bone loss through the gut-oral axis /Th17/Treg imbalance
  This study on UC-driven gut dysbiosis and Th17/Treg imbalance provides a complementary adaptive-immune perspective to the innate macrophage/pyroptosis focus here, helping readers understand how innate and adaptive immune dysfunction may be co-regulated in UC progression.